Inhibitors targeting the catalytic activity of USP2a could attack prostate cancer cells via several different mechanisms, such as i) reducing MYC levels, thus reducing proliferation and ii) increasing p53 levels leading to increased apoptosis. Here, MYC is linked to prostate carcinoma.